July 12, 2020 / 2:41 PM / 25 days ago

BRIEF-Spark Therapeutics Announces Updated Data On Spk-8011 From Phase 1/2 Clinical Trial In Hemophilia A

July 12 (Reuters) -

* SPARK THERAPEUTICS ANNOUNCES UPDATED DATA ON SPK-8011 FROM PHASE 1/2 CLINICAL TRIAL IN HEMOPHILIA A AT ISTH 2020 VIRTUAL CONGRESS

* SPARK THERAPEUTICS - ALL 14 PARTICIPANTS DEMONSTRATED RAPID CLEARANCE OF VECTOR FROM SEMEN, SERUM, SALIVA, URINE IN 2 WEEKS POST-VECTOR ADMINISTRATION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below